<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19947" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Contrast-Induced Nephropathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Modi</surname>
            <given-names>Kalgi</given-names>
          </name>
          <aff>Louisiana State University HSC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Padala</surname>
            <given-names>Sandeep A.</given-names>
          </name>
          <aff>Augusta UMC/ Medical College of Georgia</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Mohit</given-names>
          </name>
          <aff>Cleveland Clinic Foundation</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kalgi Modi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sandeep Padala declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohit Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19947.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Iodine contrast medium is essential in invasive and interventional cardiac procedures. Because of an increasing number of coronary angiography and coronary interventional procedures, the increasing use of contrast media, and the increasing number of invasive cardiac procedures being performed in high-risk patients with chronic kidney disease, diabetes mellitus, hypertension, and kidney failure due to contrast-induced nephropathy remains a growing concern. A sudden change in kidney function is a common complication of coronary angiography, and percutaneous coronary intervention, primarily because of contrast-induced acute kidney injury or contrast-induced nephropathy. This activity reviews the pathophysiology of contrast-induced nephropathy and highlights the role of the interprofessional team in its management and prevention.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the risk factors for contrast-induced nephropathy.</p></list-item><list-item><p>Review the pathophysiology of contrast-induced nephropathy.</p></list-item><list-item><p>Summarize the management of contrast-induced nephropathy.</p></list-item><list-item><p>Outline the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by contrast-induced nephropathy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19947&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19947">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19947.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>There is a lack of consensus on the definition and treatment of contrast-induced nephropathy (CIN). Currently, the understanding of&#x000a0;CIN is that it is the impairment of&#x000a0;renal function&#x000a0;gauged as either a 25% rise in serum creatinine from baseline or an increase of 0.5 mg/dL (44 &#x000b5;mol/L) in absolute serum creatinine value within 48-72 hours following intravenous contrast administration.<xref ref-type="bibr" rid="article-19947.r1">[1]</xref></p>
        <p>The renal impairment that is linked with the administration of contrast is acute, usually occurring within 2-3 days. However,&#x000a0;it has been recommended that renal impairment developing up to seven days post-contrast administration should be considered CIN if it is not attributable to any other possible cause of kidney failure. A temporal link is thus implied.<xref ref-type="bibr" rid="article-19947.r2">[2]</xref>&#x000a0;Post-contrast exposure, serum creatinine levels peak between two and five days and usually return to baseline in 14 days.</p>
        <p>Iodine contrast medium is essential in invasive and interventional cardiac procedures. Because of an increasing number of coronary angiography and coronary interventional procedures, the increasing use of contrast media, and the increasing number of invasive cardiac procedures being performed in high-risk patients with chronic kidney disease, diabetes mellitus, hypertension, and&#x000a0;kidney failure due to contrast-induced nephropathy remains a growing concern. A sudden&#x000a0;change in kidney function is a common complication of coronary angiography, and percutaneous coronary intervention, primarily because of contrast-induced acute kidney injury or contrast-induced nephropathy.<xref ref-type="bibr" rid="article-19947.r3">[3]</xref><xref ref-type="bibr" rid="article-19947.r4">[4]</xref><xref ref-type="bibr" rid="article-19947.r5">[5]</xref></p>
      </sec>
      <sec id="article-19947.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The most common cause of contrast-induced nephropathy is pre-existing chronic kidney disease. About 8% of patients with estimated glomerular filtration rate (eGFR) between 45&#x000a0;ml/min/1.73m2&#x000a0;to 60 ml/min/1.73m2, 13% of the patients with eGFR between 30&#x000a0;ml/min/1.73m2&#x000a0;to 45 ml/min/1.73m2, and 27% of patients with&#x000a0;glomerular filtration rate (GFR) less than 30 ml/min/1.73m2 develop&#x000a0;contrast-induced nephropathy&#x000a0;following contrast exposure.<xref ref-type="bibr" rid="article-19947.r6">[6]</xref><xref ref-type="bibr" rid="article-19947.r7">[7]</xref><xref ref-type="bibr" rid="article-19947.r8">[8]</xref>&#x000a0;Other clinical factors include advanced age, diabetes, peripheral heart failure, females, peripheral vascular disease, hypertension, and a left ventricular ejection fraction (LVEF) of less than 40%. Precipitating factors include acute coronary syndrome, hypotension, volume depletion, concomitant nephrotoxic medications, and anemia.</p>
        <p>Contrast media (CM) affect&#x000a0;distinct anatomic sites in the kidney and manifest adverse effects via several mechanisms. They exert Four cardinal effects:</p>
        <list list-type="bullet">
          <list-item>
            <p>A direct cytotoxic effect on the proximal tubules of the kidney</p>
          </list-item>
          <list-item>
            <p>Enhance cellular damage via reactive oxygen species</p>
          </list-item>
          <list-item>
            <p>Increase resistance to blood flow in the kidney</p>
          </list-item>
          <list-item>
            <p>Exacerbate renal vasoconstriction, particularly in the medulla which is especially important in patients with chronic kidney disease</p>
          </list-item>
        </list>
        <p>There are several risk predictor models available to predict&#x000a0;contrast-induced nephropathy&#x000a0;risk before the&#x000a0;procedure and the use of preventive measures. Gurm and colleagues used a cohort of over 68,000 percutaneous coronary intervention procedures to develop an online calculator risk predictor (http://bmc2.org/calculators/cin).</p>
        <p>Similarly, the Roxana Mehran score predictor applies the following ten variables:</p>
        <table-wrap id="article-19947.table0" position="float" orientation="portrait">
          <table style="height: 203px; width: 480px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 15px;" rowspan="1" colspan="1">1.</td>
                <td style="width: 140.974px;" rowspan="1" colspan="1">Age</td>
                <td style="width: 189.026px;" rowspan="1" colspan="1">4 points if older than 75 years old</td>
              </tr>
              <tr>
                <td style="width: 15px;" rowspan="1" colspan="1">2.</td>
                <td style="width: 140.974px;" rowspan="1" colspan="1">Anemia</td>
                <td style="width: 189.026px;" rowspan="1" colspan="1">3 points</td>
              </tr>
              <tr>
                <td style="width: 15px;" rowspan="1" colspan="1">3.</td>
                <td style="width: 140.974px;" rowspan="1" colspan="1">Use of an intra-aortic balloon pump</td>
                <td style="width: 189.026px;" rowspan="1" colspan="1">5 points</td>
              </tr>
              <tr>
                <td style="width: 15px;" rowspan="1" colspan="1">4.</td>
                <td style="width: 140.974px;" rowspan="1" colspan="1">eGFR 60 to 40</td>
                <td style="width: 189.026px;" rowspan="1" colspan="1">2 points</td>
              </tr>
              <tr>
                <td style="width: 15px;" rowspan="1" colspan="1">5.</td>
                <td style="width: 140.974px;" rowspan="1" colspan="1">eGFR 40 to 20</td>
                <td style="width: 189.026px;" rowspan="1" colspan="1">4 points</td>
              </tr>
              <tr>
                <td style="width: 15px;" rowspan="1" colspan="1">6.</td>
                <td style="width: 140.974px;" rowspan="1" colspan="1">eGFR less than 20</td>
                <td style="width: 189.026px;" rowspan="1" colspan="1">6 points</td>
              </tr>
              <tr>
                <td style="width: 15px;" rowspan="1" colspan="1">7.</td>
                <td style="width: 140.974px;" rowspan="1" colspan="1">Hypotension</td>
                <td style="width: 189.026px;" rowspan="1" colspan="1">5 points, if systolic BP less than 80 mmHg for at least one hour requiring inotropic support</td>
              </tr>
              <tr>
                <td style="width: 15px;" rowspan="1" colspan="1">8.</td>
                <td style="width: 140.974px;" rowspan="1" colspan="1">Contrast media volume</td>
                <td style="width: 189.026px;" rowspan="1" colspan="1">1 point per 100 ml</td>
              </tr>
              <tr>
                <td style="width: 15px;" rowspan="1" colspan="1">9.</td>
                <td style="width: 140.974px;" rowspan="1" colspan="1">Congestive heart failure</td>
                <td style="width: 189.026px;" rowspan="1" colspan="1">
<p>5 points</p>
</td>
              </tr>
              <tr>
                <td style="width: 15px;" rowspan="1" colspan="1">10.</td>
                <td style="width: 140.974px;" rowspan="1" colspan="1">Diabetes</td>
                <td style="width: 189.026px;" rowspan="1" colspan="1">
<p>3 points</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>A risk score of less than 6 carries a risk of 7.5% and more than 16 carries up to 57% risk.</p>
      </sec>
      <sec id="article-19947.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The prevalence of diabetes and chronic kidney disease is rising. Both of these&#x000a0;are risk factors for acute kidney injury after cardiac catheterization and percutaneous coronary interventions. Based on current definitions the incidence of contrast-induced nephropathy ranges from 2% to 30%. Most cases are completely&#x000a0;reversible within two to four weeks. The need for renal replacement therapy is rare at a rate of 1% to 4%, and of these, less than 50% require long-term renal replacement therapy. The incidence of contrast-induced nephropathy is calculated to be more than 2% in the general population. However, in high-risk groups with risk factors for kidney disease, the incidence is as high as 20% to 30%. It is reported that there is a lower risk of contrast-induced nephropathy when low osmolar contrast media&#x000a0;is used.<xref ref-type="bibr" rid="article-19947.r9">[9]</xref></p>
        <p>Contrast-induced nephropathy is the third leading cause of&#x000a0;iatrogenic&#x000a0;acute kidney injury. The commonest cause is hypoperfusion of the kidneys causing either prerenal injury or acute tubular necrosis.<xref ref-type="bibr" rid="article-19947.r10">[10]</xref>&#x000a0;Moreover, the number and the type of risk factors directly affect the incidence of renal impairment. The incidence rate also depends on the procedure, with reports in the literature&#x000a0;varying from 1.6-2.3% for diagnostic investigations to 14.5% overall in coronary intervention.<xref ref-type="bibr" rid="article-19947.r11">[11]</xref>&#x000a0;</p>
        <p>In patients older than 60 years, the incidence of CIN has been reported as 8%-16%. In patients with acute myocardial infarction who undergo coronary intervention, it has been shown that the age of 75 years or&#x000a0;more is an independent risk factor for the development of CIN.</p>
      </sec>
      <sec id="article-19947.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of contrast-induced nephropathy remains unclear. The proposed theory is a combination of vasoconstriction, ischemia, hypoxia, and direct toxic effect on renal tubular cells. The&#x000a0;hemodynamic alterations and medications can exacerbate the possibility of contrast-induced nephropathy. The risk of contrast-induced kidney injury is much higher with the arterial administration of contrast compared with venous administration of contrast.&#x000a0;Metformin can cause lactic acidosis in the setting of kidney dysfunction and acute kidney injury. The FDA recommends holding metformin on the day of contrast exposure and 48 hours after the procedure. Another cause is catheter-induced aeroembolism to the renal microvasculature. Laboratory abnormalities may include eosinophilia and eosinophilia in an acute kidney injury as a result of cholesterol atheroembolism.<xref ref-type="bibr" rid="article-19947.r8">[8]</xref></p>
        <p>Renal microcirculation depends on an interplay of hormonal, neural, paracrine, and autocrine signals. Of note are:</p>
        <list list-type="bullet">
          <list-item>
            <p>The vasodilator - nitric oxide (NO)</p>
          </list-item>
          <list-item>
            <p>The vasoconstrictors - vasopressin, adenosine, angiotensin 2, and endothelins</p>
          </list-item>
        </list>
        <p>Nitric oxide seems to be crucial, with antiplatelet, vasodilatory, anti-inflammatory, and antioxidant effects.&#x000a0;The&#x000a0;levels of asymmetrical dimethylarginine, which is an inhibitor of NO synthase, can be utilized as a marker of CIN, particularly in patients with adverse outcomes.</p>
        <p>Contrast media-mediated vasoconstriction occurs as a result of a direct action of media on vascular smooth muscle and via metabolites such as endothelin and adenosine. Additionally, it decreases water reabsorption,&#x000a0;causing an increase in interstitial pressure. This reduces GFR and compression of the vasa recta follows.&#x000a0;These mechanisms contribute to aggravating medullary hypoxemia and vasoconstriction in the kidneys in patients who already have volume depletion. &#x000a0; Finally,&#x000a0;contrast media also&#x000a0;worsens resistance to blood flow by&#x000a0;causing an increase in blood viscosity and by lowering red cell deformability. The ensuing intravascular sludging causes local ischemia and activation of reactive oxygen species leading to tubular damage at a cellular level.</p>
      </sec>
      <sec id="article-19947.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>When kidney biopsies are done, there is visible evidence of direct damage to the renal tubular epithelial cells by the contrast dye. One may note the presence of interstitial inflammation, cell vacuolization, and patch necrosis. This&#x000a0;damage to the cells is usually evident within the first 7-10 days of the injury.</p>
        <p>Direct toxic effects of contrast media on tubular epithelial cells are characterized by the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cell vacuolization</p>
          </list-item>
          <list-item>
            <p>Interstitial inflammation</p>
          </list-item>
          <list-item>
            <p>Cellular necrosis</p>
          </list-item>
        </list>
        <p>These characteristic changes, known as osmotic nephrosis, were noted in 22.3% of patients in a study. These patients underwent renal biopsy within 10 days of contrast exposure.<xref ref-type="bibr" rid="article-19947.r12">[12]</xref></p>
      </sec>
      <sec id="article-19947.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Contrast-induced nephropathy was first reported by Bartel et al. in the 1950s and was related to a fatal acute renal injury that happened following intravenous pyelography in a patient with a myeloma kidney. A transient&#x000a0;rise in creatine occurs in 15% of patients undergoing invasive procedures. Even mild contrast-induced nephropathy&#x000a0;is associated with longer hospital stays, increased cost, and higher short-term and long-term mortality. The reported incidence varies between 7% and 11% depending on the definition applied, study population, and setting. An average additional cost of more than $10,000 is associated with a contrast-induced nephropathy-related hospital stay. Contrast-induced acute kidney injury is diagnosed by following up on creatinine levels two to three days after contrast exposure.</p>
        <p>Patients suffering from contrast-induced nephropathy usually&#x000a0;have a preceding history of contrast administration, 24-48 hours&#x000a0;before&#x000a0;the presentation,&#x000a0;while undergoing a diagnostic or therapeutic procedure, such as percutaneous coronary intervention. Acute kidney injury is&#x000a0;mostly nonoliguric.</p>
        <p>A physical examination is&#x000a0;helpful in&#x000a0;ruling out other possible causes of acute nephropathies,&#x000a0;for instance, cholesterol emboli (pathognomonic findings of which&#x000a0;are blue toes and livedo reticularis) or interstitial nephritis secondary to drugs (that typically involves a rash). There may be signs of volume depletion or there could be&#x000a0;decompensated heart failure.</p>
      </sec>
      <sec id="article-19947.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Contrast-induced nephropathy is defined as a rise in serum creatinine of at least 0.5 mg/dL or a 25% increase from baseline within 48 to 72 hours after contrast exposure. The Kidney Disease Improving Global Outcome (KDIGO) definition is different, with stage 1 being a rapid rise of creatinine to greater than 0.3 mg/dL within 48 hours or the relative rise of 50% or more from baseline in 7 days or less&#x000a0;or a reduction in urine output to less than 0.5 ml/kg/hr for 6 to 12 hours. This severity is further staged based on creatinine levels, urine output, or the need for renal replacement therapy.<xref ref-type="bibr" rid="article-19947.r13">[13]</xref></p>
        <p>In contrast-induced nephropathy, serum creatinine usually begins to rise within 24 hours after the administration of contrast media, peaks between 3 and 5 days, and comes back to baseline in 7-10 days. A surrogate marker of renal function, serum cystatin C, is increased in patients with contrast-induced nephropathy.</p>
        <p>Nonspecific formed elements may appear in the urine,&#x000a0;such as&#x000a0;tubular epithelial cells, granular casts, uric acid crystals, and debris. However, they do not have a correlation with severity.</p>
        <p>It is worthwhile to do urine osmolality that tends to be less than 350 mOsm/kg. The fractional excretion of sodium (FENa) may vary a great deal. In a small number of patients with oliguric CIN, FENa is low earlier in the course, despite the absence of clinical&#x000a0;signs of volume depletion.</p>
      </sec>
      <sec id="article-19947.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The most common strategy to reduce the risk of contrast-induced nephropathy must be considered before the contrast exposure. Periprocedural hydration in chronic kidney disease patients by initiating intravenous (IV) fluid with 0.9% normal saline infusion at a rate of 1 ml/kg/hr for 6 to 12 hours before the procedure and continuing after the procedure. Some literature supports a sliding scale IV hydration protocol based on left ventricular end-diastolic pressure.&#x000a0;</p>
        <p>Bicarbonate alkalinizes the renal tubular fluid preventing free radical injury. Bicarbonate, by alkalinizing the environment, slows down that reaction Harber-Weiss reaction which otherwise would have resulted in free radical injury. It also helps to scavenge reactive oxygen species from NO, such as peroxynitrite.</p>
        <p>Bicarbonate&#x000a0;is most often given as an infusion of sodium bicarbonate at a rate of 3 mL/kg/hour an hour prior to the procedure, to be continued at a rate of 1 mL/kg/hour for six hours. However, the exact duration remains a matter of debate. According to some studies, hydration with sodium bicarbonate&#x000a0;is more protective than normal saline alone.</p>
        <p>In a clinical trial, there was no consistent benefit to justify the routine administration of sodium bicarbonate in patients undergoing cardiac catheterization. Similarly, the Acetylcysteine for Contrast-Induced Nephropathy trial found no difference between acetylcysteine and placebo in the prevention of&#x000a0;contrast-induced neuropathy&#x000a0;or need for dialysis.</p>
        <p>It is reasonable to pretreat patients with high-intensity statin before contrast use.&#x000a0;A meta-analysis observed that pretreatment with rosuvastatin could significantly decrease the incidence of contrast-induced&#x000a0;nephropathy (OR 0.49, P less than 0.001). However, rosuvastatin did not&#x000a0;appear to be effective for&#x000a0;the prevention of contrast-induced&#x000a0;nephropathy in patients already suffering from chronic kidney disease&#x000a0;undergoing elective cardiac catheterization.<xref ref-type="bibr" rid="article-19947.r14">[14]</xref></p>
        <p>Fenoldopam, a dopamine receptor agonist, did not have any benefit in clinical trials. Ascorbic acid 1 g to 3 g for one to three days periprocedural has been shown to reduce&#x000a0;contrast-induced neuropathy&#x000a0;by 33%. The benefit of hemofiltration has been demonstrated in an&#x000a0;isolated trial. During the procedure, one can use a smaller guide catheter, minimize contrast use, avoid ventriculogram, biplane coronary angiography, low osmolar, or iso-osmolar nonionic contrast agent, and maximum allowable contrast dose to be three times the estimated GFR.<xref ref-type="bibr" rid="article-19947.r15">[15]</xref><xref ref-type="bibr" rid="article-19947.r16">[16]</xref><xref ref-type="bibr" rid="article-19947.r17">[17]</xref></p>
      </sec>
      <sec id="article-19947.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Following are some important differential diagnoses that need to be considered while making a diagnosis of contrast-induced nephropathy:</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute renal failure</p>
          </list-item>
          <list-item>
            <p>Embolic renal disease</p>
          </list-item>
          <list-item>
            <p>Interstitial nephritis</p>
          </list-item>
          <list-item>
            <p>Acute tubular necrosis</p>
          </list-item>
          <list-item>
            <p>Renal artery stenosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19947.s11" sec-type="Staging">
        <title>Staging</title>
        <p>Several scoring systems have been developed to predict contrast-induced&#x000a0;kidney injury and the following are the risk factors:</p>
        <list list-type="bullet">
          <list-item>
            <p>Use of an intra-aortic&#x000a0;balloon pump</p>
          </list-item>
          <list-item>
            <p>Congestive heart failure (CHF)</p>
          </list-item>
          <list-item>
            <p>Hypotension</p>
          </list-item>
          <list-item>
            <p>Elevated creatinine (More than 1.5)</p>
          </list-item>
          <list-item>
            <p>Age greater than 75</p>
          </list-item>
          <list-item>
            <p>Diabetes</p>
          </list-item>
          <list-item>
            <p>Anemia</p>
          </list-item>
          <list-item>
            <p>Use of contrast volume more than 100 ml</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19947.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Overall, the prognosis depends on patients' co-morbidities including but not limited to baseline renal function. Depending upon the scoring system, following contrast administration, there can be a probability of CIN. Generally, it is reversible and biopsy is rarely needed for the diagnosis.</p>
        <p>CIN is normally a self-resolving process, with renal function getting back to normal within 7-14 days of the administration of contrast. Fewer than one-third of patients develop some&#x000a0;level of residual renal impairment.</p>
        <p>Renal replacement therapy&#x000a0;is required in less than 1% of the cases, with a slightly raised incidence in patients who are either having an underlying renal impairment (3.1%) or undergoing primary percutaneous coronary intervention for myocardial infarction (3%). However, in patients suffering from diabetes and severe kidney failure, the rate of dialysis may be as high as 12%. &#x000a0; 18% of CIN patients who&#x000a0;require dialysis end up&#x000a0;needing it permanently. However, the majority of these patients have severe renal insufficiency and coexisting diabetic nephropathy. They would have progressed to&#x000a0;requiring dialysis regardless of the&#x000a0;development of CIN. &#x000a0; There is a growing understanding&#x000a0;that AKI after contrast media exposure can be an indicator of CRF or ESRF. In an observational study, 3986 patients were included in which coronary angiography was performed, 12.1% of patients&#x000a0;developed contrast-induced AKI, and of those, 18.6% sustained permanent renal damage.<xref ref-type="bibr" rid="article-19947.r18">[18]</xref></p>
        <p>Patients who need dialysis have a worse prognosis, with 35.7% inhospital mortality reported (compared to 7.1% in the nondialysis cohort) and 2-year survival of only 19%.</p>
        <p>In&#x000a0;a study on the long-term mortality associated with CIN after&#x000a0;PCI in patients with or without CKD, CIN was&#x000a0;observed to be significantly&#x000a0;linked with long-term mortality in the&#x000a0;whole group (hazard ratio 2.26, 95% confidence interval 1.62 to 2.29,&#x000a0;<italic toggle="yes">P </italic>value less than&#x000a0;0.0001) and in patients having CKD (hazard ratio 2.62, 95% confidence interval 1.91 to 3.57,&#x000a0;<italic toggle="yes">P</italic>&#x000a0;value less than 0.0001) but not in patients without CKD (hazard ratio 1.23, 95% confidence interval 0.47 to 2.62,&#x000a0;<italic toggle="yes">P</italic>&#x000a0;is equal to 0.6). The&#x000a0;occurrence of CIN in patients with CKD was found to be 11% and 2% in patients without CKD.<xref ref-type="bibr" rid="article-19947.r19">[19]</xref></p>
      </sec>
      <sec id="article-19947.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Following are the complications that are associated with&#x000a0;contrast-induced nephropathy:</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute renal failure</p>
          </list-item>
          <list-item>
            <p>Acute on chronic renal failure</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity reactions</p>
          </list-item>
          <list-item>
            <p>Fluid overload</p>
          </list-item>
          <list-item>
            <p>Pulmonary edema</p>
          </list-item>
          <list-item>
            <p>Contrast-induced thyroid dysfunction</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19947.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Contrast-induced nephropathy is usually reversible and can present with a mild reduction in GFR that&#x000a0;tends to improve within three to seven days. Most of the patients return to, or close to, their baseline estimated GFR.&#x000a0;People with advanced renal failure may temporarily need dialysis following contrast administration.</p>
      </sec>
      <sec id="article-19947.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Approximately 42% of deaths among patients with end-stage renal disease (ESRD) are due to a cardiovascular event. Routine dialysis is not the recommendation in a patient with end-stage renal disease undergoing cardiac catheterization. They can be maintained on their routine dialysis schedule.&#x000a0;</p>
        <p>It is important to recognize that precaution is needed in a patient with a transplanted kidney undergoing cardiac catheterization. Instrumentation of the vessel that supplies the transplanted kidney should be avoided. Additionally, contrast should be used judiciously even with normal GFR, avoid indwelling arterial or venous catheters, and use of vascular closure device due to the risk of infection.</p>
        <p>Assessment of acute kidney injury with serum creatinine has poor sensitivity and specificity. Several new markers have been identified with most of the current interest focused on cystatin C, neutrophil gelatinase-associated lipocalin, interleukin 18, and kidney injury molecule 1.</p>
      </sec>
      <sec id="article-19947.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Because&#x000a0;contrast-induced&#x000a0;renal injury leads to high morbidity, prolonged admission, and increased health care costs, the goal is today is focused on prevention. Besides physicians, both the nurse and pharmacist need to be aware of the patient's medical history and concomitant use of other medications. A detailed history of&#x000a0;risk factors like diabetes, heart failure, and hypertension is critical. Any patient prescribed an intervention procedure that uses contrast dye must be fully assessed for a history of diabetes and renal function. These individuals may be better served with another imaging test that does not require the use of contrast. If there is no choice, then the patient must be educated about the possibility of kidney injury and the need for dialysis. The pharmacist should ensure that all nephrotoxic drugs are discontinued prior to the test. The nurse should make sure that the patient is well hydrated both before and after the test. The drug metformin should&#x000a0;be withheld for 48 hours and restarted if the renal function is normal. Only through proper communication and monitoring can the frequency of contrast-induced&#x000a0;renal injury be lowered.<xref ref-type="bibr" rid="article-19947.r20">[20]</xref><xref ref-type="bibr" rid="article-19947.r21">[21]</xref><xref ref-type="bibr" rid="article-19947.r22">[22]</xref>(Level V)</p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>Contrast-induced&#x000a0;kidney injury is in most cases not a permanent injury and most patients will see a recovery of renal function within 10-14 days. However, in patients with underlying renal disease, diabetes, or hypertension, about 20-30% of patients will have residual impairment of renal function. Dialysis may be required in less than 1-3% of non-diabetic patients, but in diabetics, dialysis may be required in anywhere from 10-15% of cases. Of those who do required dialysis, at least 20% may end up on permanent dialysis. The presence of persistent kidney damage after the use of contrast highlights the importance of hydration and avoidance of contrast when other imaging modalities are available.<xref ref-type="bibr" rid="article-19947.r7">[7]</xref><xref ref-type="bibr" rid="article-19947.r23">[23]</xref><xref ref-type="bibr" rid="article-19947.r24">[24]</xref>(Level V)</p>
      </sec>
      <sec id="article-19947.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19947&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19947">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/kidney-health/contrast-induced-nephropathy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=19947">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19947/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19947">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19947.s18">
        <title>References</title>
        <ref id="article-19947.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moro</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Strauch</surname>
                <given-names>JGN</given-names>
              </name>
              <name>
                <surname>Groto</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Toregeani</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Creatinine level variation in patients subjected to contrast-enhanced tomography: a meta-analysis.</article-title>
            <source>J Vasc Bras</source>
            <year>2021</year>
            <volume>20</volume>
            <fpage>e20200161</fpage>
            <pub-id pub-id-type="pmid">34267786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19947.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murphy</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Parfrey</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Contrast nephropathy.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>177</fpage>
            <page-range>177-182</page-range>
            <pub-id pub-id-type="pmid">10616853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19947.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elserafy</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Okasha</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hegazy</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Prevention of contrast induced nephropathy by ischemic preconditioning in patients undergoing percutaneous coronary angiography.</article-title>
            <source>Egypt Heart J</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>70</volume>
            <issue>2</issue>
            <fpage>107</fpage>
            <page-range>107-111</page-range>
            <pub-id pub-id-type="pmid">30166891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19947.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oweis</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Alshelleh</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Daoud</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Smadi</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Alzoubi</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>Inflammatory milieu in contrast-induced nephropathy: a prospective single-center study.</article-title>
            <source>Int J Nephrol Renovasc Dis</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>211</fpage>
            <page-range>211-215</page-range>
            <pub-id pub-id-type="pmid">30147351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19947.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ul Abideen</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Mahmud</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Salih</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arif</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rasheed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zafran</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Contrast-induced Acute Kidney Injury in Patients with Liver Cirrhosis: A Retrospective Analysis.</article-title>
            <source>Cureus</source>
            <year>2018</year>
            <month>May</month>
            <day>29</day>
            <volume>10</volume>
            <issue>5</issue>
            <fpage>e2707</fpage>
            <pub-id pub-id-type="pmid">30062081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19947.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patschan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>[Acute Kidney Injury, AKI - Update 2018].</article-title>
            <source>Dtsch Med Wochenschr</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>143</volume>
            <issue>15</issue>
            <fpage>1094</fpage>
            <page-range>1094-1096</page-range>
            <pub-id pub-id-type="pmid">30060280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19947.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDonald</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Kolbe</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Kallmes</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>Postcontrast Acute Kidney Injury in Pediatric Patients: A Cohort Study.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>72</volume>
            <issue>6</issue>
            <fpage>811</fpage>
            <page-range>811-818</page-range>
            <pub-id pub-id-type="pmid">30041876</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19947.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hossain</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Costanzo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cosentino</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Qaisar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Asif</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vachharajani</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Contrast-induced nephropathy: Pathophysiology, risk factors, and prevention.</article-title>
            <source>Saudi J Kidney Dis Transpl</source>
            <year>2018</year>
            <season>Jan-Feb</season>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-9</page-range>
            <pub-id pub-id-type="pmid">29456202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19947.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hiremath</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Akbari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Chow</surname>
                <given-names>BJW</given-names>
              </name>
            </person-group>
            <article-title>Are iso-osmolar, as compared to low-osmolar, contrast media cost-effective in patients undergoing cardiac catheterization? An economic analysis.</article-title>
            <source>Int Urol Nephrol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>50</volume>
            <issue>8</issue>
            <fpage>1477</fpage>
            <page-range>1477-1482</page-range>
            <pub-id pub-id-type="pmid">29687326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19947.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehta</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Pascual</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Soroko</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Himmelfarb</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ikizler</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Paganini</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Chertow</surname>
                <given-names>GM</given-names>
              </name>
              <collab>Program to Improve Care in Acute Renal Disease</collab>
            </person-group>
            <article-title>Spectrum of acute renal failure in the intensive care unit: the PICARD experience.</article-title>
            <source>Kidney Int</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>66</volume>
            <issue>4</issue>
            <fpage>1613</fpage>
            <page-range>1613-21</page-range>
            <pub-id pub-id-type="pmid">15458458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19947.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCullough</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Wolyn</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rocher</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>WW</given-names>
              </name>
            </person-group>
            <article-title>Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality.</article-title>
            <source>Am J Med</source>
            <year>1997</year>
            <month>Nov</month>
            <volume>103</volume>
            <issue>5</issue>
            <fpage>368</fpage>
            <page-range>368-75</page-range>
            <pub-id pub-id-type="pmid">9375704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19947.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moreau</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Noel</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Droz</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Proximal renal tubular vacuolization induced by iodinated contrast media, or so-called "osmotic nephrosis".</article-title>
            <source>Invest Radiol</source>
            <year>1993</year>
            <month>Feb</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>187</fpage>
            <page-range>187-90</page-range>
            <pub-id pub-id-type="pmid">8444577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19947.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katsiki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tsioufis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hahalis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Athyros</surname>
                <given-names>VG</given-names>
              </name>
            </person-group>
            <article-title>Contrast-induced acute kidney injury: beware of the risk after coronary angiography.</article-title>
            <source>Expert Rev Cardiovasc Ther</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>73</fpage>
            <pub-id pub-id-type="pmid">29281937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19947.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>YX</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>YZ</given-names>
              </name>
            </person-group>
            <article-title>Rosuvastatin Treatment for Preventing Contrast-Induced Acute Kidney Injury After Cardiac Catheterization: A Meta-Analysis of Randomized Controlled Trials.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>94</volume>
            <issue>30</issue>
            <fpage>e1226</fpage>
            <pub-id pub-id-type="pmid">26222855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19947.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yen</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Sung</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>YH</given-names>
              </name>
            </person-group>
            <article-title>Clinical presentations of contrast-induced encephalopathy in end-stage renal disease.</article-title>
            <source>Intern Med J</source>
            <year>2018</year>
            <month>May</month>
            <volume>48</volume>
            <issue>5</issue>
            <fpage>604</fpage>
            <page-range>604-605</page-range>
            <pub-id pub-id-type="pmid">29722192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19947.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matthews</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Acute Kidney Injury and Iodinated Contrast Media.</article-title>
            <source>Radiol Technol</source>
            <year>2018</year>
            <month>May</month>
            <volume>89</volume>
            <issue>5</issue>
            <fpage>467CT</fpage>
            <page-range>467CT-477CT</page-range>
            <pub-id pub-id-type="pmid">29793919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19947.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nijssen</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Nelemans</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Rennenberg</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>van Ommen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wildberger</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of Safety Guidelines on the Use of Iodinated Contrast Material: Conundrum Continued.</article-title>
            <source>Invest Radiol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>53</volume>
            <issue>10</issue>
            <fpage>616</fpage>
            <page-range>616-622</page-range>
            <pub-id pub-id-type="pmid">29762257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19947.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maioli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Toso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leoncini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gallopin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Musilli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bellandi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Persistent renal damage after contrast-induced acute kidney injury: incidence, evolution, risk factors, and prognosis.</article-title>
            <source>Circulation</source>
            <year>2012</year>
            <month>Jun</month>
            <day>26</day>
            <volume>125</volume>
            <issue>25</issue>
            <fpage>3099</fpage>
            <page-range>3099-107</page-range>
            <pub-id pub-id-type="pmid">22592896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19947.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morimoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Akao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Furukawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nakagawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shizuta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ehara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Taniguchi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Doi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nishiyama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ozasa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hoshino</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mitsuoka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Toma</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Haruna</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Relation of contrast-induced nephropathy to long-term mortality after percutaneous coronary intervention.</article-title>
            <source>Am J Cardiol</source>
            <year>2014</year>
            <month>Aug</month>
            <day>01</day>
            <volume>114</volume>
            <issue>3</issue>
            <fpage>362</fpage>
            <page-range>362-8</page-range>
            <pub-id pub-id-type="pmid">24927973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19947.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qian</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Prevention of contrast-induced nephropathy by adequate hydration combined with isosorbide dinitrate for patients with renal insufficiency and congestive heart failure.</article-title>
            <source>Clin Cardiol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>21</fpage>
            <page-range>21-25</page-range>
            <pub-id pub-id-type="pmid">30054906</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19947.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lou</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Contrast-induced nephropathy prevention by remote ischemic preconditioning: Effect of diabetes mellitus.</article-title>
            <source>Int J Cardiol</source>
            <year>2018</year>
            <month>Oct</month>
            <day>01</day>
            <volume>268</volume>
            <fpage>41</fpage>
            <pub-id pub-id-type="pmid">30041798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19947.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Samadian</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dalili</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mahmoudieh</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ziaei</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Contrast-induced Nephropathy: Essentials and Concerns.</article-title>
            <source>Iran J Kidney Dis</source>
            <year>2018</year>
            <month>May</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>135</fpage>
            <page-range>135-141</page-range>
            <pub-id pub-id-type="pmid">29891742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19947.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neugarten</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Golestaneh</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kolhe</surname>
                <given-names>NV</given-names>
              </name>
            </person-group>
            <article-title>Sex differences in acute kidney injury requiring dialysis.</article-title>
            <source>BMC Nephrol</source>
            <year>2018</year>
            <month>Jun</month>
            <day>08</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>131</fpage>
            <pub-id pub-id-type="pmid">29884141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19947.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Windpessl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kronbichler</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pro: Contrast-induced nephropathy-should we try to avoid contrast media in patients with chronic kidney disease?</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2018</year>
            <month>Aug</month>
            <day>01</day>
            <volume>33</volume>
            <issue>8</issue>
            <fpage>1317</fpage>
            <page-range>1317-1319</page-range>
            <pub-id pub-id-type="pmid">29868731</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
